Home Cart Sign in  
Chemical Structure| 355025-24-0 Chemical Structure| 355025-24-0

Structure of Ki16425
CAS No.: 355025-24-0

Chemical Structure| 355025-24-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively, shows no activity at LPA4, LPA5, LPA6.

Synonyms: Debio 0719

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ki16425

CAS No. :355025-24-0
Formula : C23H23ClN2O5S
M.W : 474.96
SMILES Code : O=C(O)CCSCC1=CC=C(C2=C(NC(OC(C3=CC=CC=C3Cl)C)=O)C(C)=NO2)C=C1
Synonyms :
Debio 0719
MDL No. :MFCD06798341
InChI Key :LLIFMNUXGDHTRO-UHFFFAOYSA-N
Pubchem ID :10367662

Safety of Ki16425

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ki16425

GPCR

Isoform Comparison

Biological Activity

Target
  • LPA2

    LPA2, Ki:6.5 μM

  • LPA1

    LPA1, Ki:0.34 μM

  • LPA3

    LPA3, Ki:0.93 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
PC-3M-luc-C6 cells 1 µM 12 hours Ki16425 completely inhibited LPA-induced migration of PC-3M-luc-C6 cells Exp Mol Med. 2014 Jul 4;46(7):e104.
Cardiomyocytes 1 µM 1-5 days To evaluate the effect of LPA on cardiomyocyte proliferation, results showed that LPA induced cardiomyocyte proliferation in a time- and concentration-dependent manner Theranostics. 2020 Aug 29;10(24):10892-10907.
786-O cells 1 µM 30 minutes Ki16425 effectively attenuated LPA-induced cell signaling and invasion Clin Cancer Res. 2013 Dec 1;19(23):6461-72.
UMRC3 cells 1 µM 30 minutes Ki16425 effectively attenuated LPA-induced cell signaling and invasion Clin Cancer Res. 2013 Dec 1;19(23):6461-72.
Cardiomyocytes 1, 5, 10 µM 48 hours To evaluate the effect of different concentrations of LPA on cardiomyocyte proliferation, results showed that LPA increased the number of EdU-positive cardiomyocytes in a concentration-dependent manner Theranostics. 2020 Aug 29;10(24):10892-10907.
Human primary valve interstitial cells 1  µM 7 days Ki16425 negated platelet-induced mineralization of VIC cultures Eur Heart J. 2019 May 1;40(17):1362-1373.
Valve interstitial cells (VICs) 10 µM 7 days Ki16425 prevented OxLDL-induced mineralization of VICs Cardiovasc Res. 2017 Sep 1;113(11):1351-1363.
Mouse Embryo Fibroblast (MEF) 10 µM Ki16425 completely blocked AOCP-induced MEF cell migration, indicating that LPA is the major component in AOCP responsible for inducing MEF cell migration. Exp Mol Med. 2008 Aug 31;40(4):445-52.
4T1 cells 60 nM Debio-0719 had little antiproliferative effect on 4T1 cells but inhibited their motility. J Natl Cancer Inst. 2012 Sep 5;104(17):1306-19.
MDA-MB-231T cells 60 nM Debio-0719 inhibited the migration ability of MDA-MB-231T cells. J Natl Cancer Inst. 2012 Sep 5;104(17):1306-19.
MDA-BO2/GFP cells 0-10 µM Ki16425 dose-dependently inhibited LPA-induced proliferation of MDA-BO2/GFP cells. Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9643-8.
CHO/H92523wt cells 0-10 µM Ki16425 dose-dependently inhibited LPA-induced proliferation of CHO/H92523wt cells. Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9643-8.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice LPA-induced hydrocephalus model Intracranial injection 1 mg/kg Single injection, 15 minutes before LPA injection Pretreatment with Ki16425 resulted in 44% of animals exhibiting no VM, but this reduction was not statistically significant from controls. Sci Adv. 2019 Oct 9;5(10):eaax2011
Mice Experimental Autoimmune Encephalomyelitis (EAE) model Intraperitoneal injection 15 and 30 mg/kg Once daily until the end of the experiment Ki16425 significantly deteriorated motor disability in EAE mice, increased spinal cord demyelination, inflammation, cellular infiltration, and blood-brain barrier disruption. The underlying mechanism was associated with the overproduction of reactive oxygen species (ROS) via NOX2 and NOX3. J Neuroinflammation. 2021 Oct 19;18(1):240
Mice 4T1 spontaneous metastasis model Subcutaneous injection 15 mg/kg Twice daily, continued until the end of the experiment Debio-0719 significantly inhibited the metastasis of 4T1 cells to the liver and lungs but had no effect on primary tumor size. J Natl Cancer Inst. 2012 Sep 5;104(17):1306-19.
SD rats Myocardial infarction model Intraperitoneal injection 20 mg/kg Daily from the day of birth To evaluate the effect of Ki16425 on cardiomyocyte proliferation, results showed that Ki16425 significantly reduced the number of pH3-, BrdU- and Ki67-positive cardiomyocytes Theranostics. 2020 Aug 29;10(24):10892-10907.
BALB/c Nude mice RCC xenograft models Subcutaneously 20 mg/kg Once daily for 48 days Ki16425 markedly inhibited RCC tumor growth and reduced tumor proliferation and angiogenesis Clin Cancer Res. 2013 Dec 1;19(23):6461-72.
NMRI nu/nu mice Breast cancer bone metastasis model Subcutaneous injection 20 mg/kg Once daily for 16 days Ki16425 significantly inhibited the progression of bone metastasis, reducing bone destruction and tumor burden. Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9643-8.
Mice LDLR-/-apoB100/100IGFII transgenic mice Intraperitoneal injection 5 mg/kg/day Once daily for 5 weeks Ki16425 abrogated platelet-induced progression of aortic valve calcification Eur Heart J. 2019 May 1;40(17):1362-1373.
Mice LDLR-/-/ApoB100/100/IGFII transgenic mice Intraperitoneal injection 5 mg/kg/day Once daily for 3 months Ki16425 reduced the progression rate of CAVS and decreased hydroxyapatite deposition in aortic valve leaflets Cardiovasc Res. 2017 Sep 1;113(11):1351-1363.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.53mL

2.11mL

1.05mL

21.05mL

4.21mL

2.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories